Navigation Links
REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder
Date:9/7/2009

ns and their patients".

Clinical trials showed the incidence of dry mouth, and constipation also occurs less frequently in patients on Regurin(R) XL compared to all other antimuscarinic agents, and approximately 50% less than Regurin(R) 20mg twice daily(9,10). In addition, Regurin(R) XL has a low potential for interaction with concomitantly administered medications.(11- 13).

Geoff McMillan, Chief Executive Officer of SEP, said: "As a young Company with a focus on Urology, the launch of Regurin XL is very exciting. Urinary incontinence is a very common and embarrassing problem and we believe that Regurin XL offers significant benefits for patients, their physicians and the health service as a whole."

Regurin(R) XL is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with OAB.

Exclusive distribution rights in the UK for Regurin(R) XL (trospium chloride), have been granted to Specialty European Pharma Ltd (SEP), a UK based, urology focused, specialty pharmaceutical company by Rottapharm|Madaus.

About Regurin(R) XL

Regurin is trospium chloride, a member of the anti-muscarinic class, used to treat the symptoms of OAB. The efficacy has been well established. Trospium chloride has been recommended by NICE for the second line treatment of UI in women after immediate release oxybutynin(14). Regurin XL has a high selectivity for two receptors in the detrusor muscle, M sub(2) and M sub(3)(15).

Regurin(R) XL is a quaternary amine: as such it is a positively charged molecule that does not cross the blood brain barrier or the blood eye barrier(2,4,7) hence unwanted side effects such as impairment of cognitive function are minimal2-7 - an important consideration especially for the elderly population.

    About Speciality European Pharma
'/>"/>
SOURCE Speciality European Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
2. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
3. New Data Presented at AUAs Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
4. MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
5. FoodBizDaily.com Announces New Free Report - International Trade Opportunity: The Brazilian Acai Berry
6. Arcadia HealthCares DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care
7. Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
8. Intense Daily Workout May Keep Cancer at Bay
9. Life after chemotherapy: Daily tasks, quality of life may be affected, MU researcher finds
10. U.S. Census Bureau Daily Feature for July 21
11. FertilityAuthority Introduces E-Newsletter, The Daily Shot
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, ... , Bank of America and Merrill Lynch 2009 ... 8:40 a.m. EDT, Bernstein,s ... 2009, 9:00 a.m. EDT, ...
... (Nasdaq: WCRX ) announced today that one ... ("Mayne") have filed a second lawsuit against Mylan Pharmaceuticals ... for the District of New Jersey for infringement of ... covers DORYX, a tetracycline-class oral antibiotic. The lawsuit ...
... better understood after taking hands-on approach , , FRIDAY, May ... specific training and tools can help young doctors do ... patients. , Seniors face added challenges with prescriptions, ... one time. Avoiding their greater susceptibility to side effects ...
... Award Honoring the Work of Oncology , NursesSAN ANTONIO, ... CURE magazine,s 2009 Extraordinary Healer Award for Oncology ... during a special reception at the Oncology Nursing Society,s ... patients and caregivers submitted nominations. The winner, Christine ...
... continues; Obama urges calm; global cases total 331 in 11 ... -- The number of confirmed swine flu cases in the ... health officials reported on Friday. , "That,s up eight states ... the U.S. Centers for Disease Control and Prevention,s science ...
... May 1 As the world sits on the ... attempting to reduce the ranks of personnel most skilled ... representing more than 20,000 Registered Nurses in 89 bargaining ... hospitals to reopen contracts regarding wages. In the ...
Cached Medicine News:Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 2Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 3Health News:Prescription Training Puts Docs in Shoes of Older Patients 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 2Health News:Swine Flu Infections Now at 141 in 19 U.S. States 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 4Health News:Swine Flu Infections Now at 141 in 19 U.S. States 5Health News:Swine Flu Infections Now at 141 in 19 U.S. States 6Health News:Swine Flu Infections Now at 141 in 19 U.S. States 7Health News:Swine Flu Infections Now at 141 in 19 U.S. States 8Health News:Swine Flu Infections Now at 141 in 19 U.S. States 9Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 2Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 3
(Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Neuro Kinetics, Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers of ... vestibular and neurological conditions, said today that it co-presented ... conference meeting in Scottsdale, Arizona. The research ... clinical testing that can be conducted with its medical ...
... 2011 IRIDEX Corporation (Nasdaq: IRIX ) today reported ... improved financial results for the fourth quarter ended January 1, 2011. ... per share, up from $0.5 million or $0.05 per diluted share ... to $12.2 million in the 2010 fourth quarter, up 6% from ...
Cached Medicine Technology:Neuro Kinetics Presenting New Balance & Dizziness Research at American Balance Society Conference 2IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 2IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 3IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 4IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 5